Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
19 May 2014

BNC105 PHASE I OVARIAN CANCER TRIAL UPDATE

- **Data to be presented at the American Society of Clinical Oncology (ASCO) Conference**

Bionomics Limited (ASX:BNO, ADR:BMICY) will present an update on the BNC105 Phase I ovarian cancer trial during a poster highlights session at the American Society for Clinical Oncology (ASCO) Annual Meeting on Monday 2 June in Chicago, IL.

ASCO is the premier oncology event on the calendar attracting more than 25,000 oncology professionals including major pharmaceutical company representatives. It runs for five days commencing Friday 30 May.

Bionomics' presentation, *A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse*, will report updated Phase I data from a multinational multi-centre Phase I/II clinical trial. The trial evaluates BNC105 in combination with the current standard therapy of carboplatin and gemcitabine in patients with ovarian cancer who previously responded to treatment but later progressed with platinum agents.

For those attending the meeting the poster presentation and discussion session can be seen at the following times and locations:

Poster:	8:00am-11:00am, Monday 2 June (Rm E354b, Poster Board #14)
Discussion:	11:30am-12:45pm, Monday 2 June (Rm E354a)

The poster will be presented by Dr Danny Rischin of the Peter MacCallum Cancer Institute in Melbourne. The study is being conducted by the Australian and New Zealand Gynaecological Oncology Group (ANZGOG) working with the National Health and Medical Research Council Clinical Trials Centre (NH&MRC CTC) in Australia and the Hoosier Oncology Group in the United States.

Bionomics will be represented at ASCO by Chief Medical Officer Dr Jose Iglesias, VP Research & Development Dr Gabriel Kremmidiotis and VP Business Development
Dr Forrest Fuller.

A copy of the abstract can be accessed on the ASCO website via following link:

http://abstracts.asco.org/144/AbstView_144_130216.html

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited
Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co and Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.